
AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure is a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. With its diverse product line and focus on key growth areas, the company is well-positioned for continued revenue growth. Additionally, its recent financial performance demonstrates improving profitability and positive investor sentiment, making it an attractive stock for investors in the healthcare sector.
Bears say
AtriCure is facing headwinds in its minimally invasive ablation platform due to PFA-related challenges which continue to decline year-over-year. Additionally, the company remains cautious in terms of its outlook for 2026 due to the ongoing decline in its U.S. hybrid business. There is potential for upside if the company sees stronger adoption of its new products and improvement in margin and EBITDA growth, as well as an increase in free cash flow.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares